<DOC>
	<DOCNO>NCT03030066</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) anti-tumor activity DS-1001b patient gliomas harbor IDH1-R132 mutation .</brief_summary>
	<brief_title>Study DS-1001b Patients With Gene IDH1-Mutated Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>1 . Has histologically confirm glioma IDH1R132 mutation 2 . Has disease recur progress follow standard treatment include radiotherapy 3 . Has measurable lesion ( ) per RANO criterion 4 . Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 1 . Has significant symptom increase intracranial pressure 2 . Has another active neoplasm 3 . Has active infection require systemic treatment 4 . Has history severe cardiac disease 5 . Has prior treatment inhibitor target mutant IDH1 6 . Has investigational drug treatment within 4 week prior first dose study treatment 7 . Is pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DS-1001b</keyword>
	<keyword>IDH1 mutation</keyword>
	<keyword>Developmental Phase I</keyword>
	<keyword>Glioma</keyword>
</DOC>